Valeant's looming M&A hiatus deals blow to investment banks
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Trump says Canada's Bombardier must build jets in US or lose market access
- Qualcomm to issue warrant to Amazon for up to 25M shares
- Wall St slips as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Cowen Raises Price Target on AT&T (T) After Updating Model to Reflect Company Changes
October 27, 2015 10:24 AM EDTCowen reiterated an Outperform rating on AT&T (NYSE: T), and raised the price target to $41.00 (from $40.00), after updating model to reflect the new way in which the company breaks out revenue.
Analyst Colby Synesael commented, "We are updating our... More
Endo Int'l (ENDP), BioDelivery Sciences (BDSI) Announce FDA Approval of BELBUCA as Chronic Pain Treatment
October 26, 2015 6:26 AM EDTEndo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) and BioDelivery Sciences International, Inc. (NASDAQ: BDSI), announced today that the U.S. Food and Drug Administration (FDA) has approved BELBUCA (buprenorphine) buccal film for use in patients with chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. BELBUCA, which is the first and only buprenorphine developed with a dissolving film that is absorbed through the inner lining of the cheek for chronic pain management, is... More
UBS Reiterates Buy on AT&T (T) Following 3Q Earnings
October 23, 2015 10:19 AM EDTUBS reiterated a Buy rating and $42.00 price target on AT&T (NYSE: T), following the company's 3Q earnings results. AT&T reported 3Q EPS of $0.74, equating to 14% yoy growth. 4Q seasonality should not be as bad as in past years, suggesting... More
